The FDA has approved Trodelvy for previously treated HR-positive, HER2-negative breast cancer, Gilead said Friday. To be eligible for the therapy, patients must have tried endocrine therapy and at least two additional therapies in the metastatic setting.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,